The genetically engineered probiotic, already in clinical trials, may ease patients’ strict dietary regimes.

In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.

Biotech stocks fell in response to the news. 

A team of Stanford University researchers say that administering young people’s blood plasma to Alzheimer’s patients could improve cognitive function, but the results have been criticized.

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.

The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

Henri Termeer helped usher the biotech company into an industry behemoth.